Errata (DOI:10.1016/S1474-4422(09)70238-8);Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria

The Lancet Neurology

Volumn 8, Issue 12, 2009, Pages 1150-1157

  Dickson, Dennis W ^a   Braak, Heiko ^b   Duda, John E ^c   Duyckaerts, Charles ^d   Gasser, Thomas ^e   Halliday, Glenda M ^f   Hardy, John ^g   Leverenz, James B ^h   Del Tredici, Kelly ^b   Wszolek, Zbigniew K ^a   Litvan, Irene ⁱ  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF ULM   (Germany)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e UNIVERSITY OF TÜBINGEN   (Germany)

^f NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN;

CELL LOSS; COGNITIVE DEFECT; DISEASE SEVERITY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; LEWY BODY; NERVE CELL; NEUROLOGIC EXAMINATION; NEUROPATHOLOGY; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

ALPHA-SYNUCLEIN; HUMANS; LEWY BODIES; PARKINSON DISEASE;

EID: 71849092190     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(10)70012-0     Document Type: Erratum

References (93)

1. Hyman B.T., and Trojanowski J.Q. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol 56 (1997) 1095-1097
2. McKeith I.G., Dickson D.W., Lowe J., et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65 (2005) 1863-1872
3. Lowe J. Establishing a pathological diagnosis in degenerative dementias. Brain Pathol 8 (1998) 403-406
4. Hornykiewicz O. Basic research on dopamine in Parkinson's disease and the discovery of the nigrostriatal dopamine pathway: the view of an eyewitness. Neurodegener Dis 5 (2008) 114-117
5. Fearnley J.M., and Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114 (1991) 2283-2301
6. Greffard S., Verny M., Bonnet A.M., et al. Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. Arch Neurol 63 (2006) 584-588
7. Mackenzie I.R., Neumann M., Bigio E.H., et al. Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol 117 (2009) 15-18
8. Farrer M.J., Hulihan M.M., Kachergus J.M., et al. DCTN1 mutations in Perry syndrome. Nat Genet 41 (2009) 163-165
9. Farrer M., Chan P., Chen R., et al. Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol 50 (2001) 293-300
10. Pramstaller P.P., Schlossmacher M.G., Jacques T.S., et al. Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers. Ann Neurol 58 (2005) 411-422
11. Hasegawa K., Stoessl A.J., Yokoyama T., Kowa H., Wszolek Z.K., and Yagishita S. Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes. Parkinsonism Relat Disord 15 (2009) 300-306
12. Gasser T. Update on the genetics of Parkinson's disease. Mov Disord 22 suppl 17 (2007) S343-S350
13. Forman M.S., Lee V.M., and Trojanowski J.Q. Nosology of Parkinson's disease: looking for the way out of a quagmire. Neuron 47 (2005) 479-482
14. Kovacs G.G., Alafuzoff I., Al-Sarraj S., et al. Mixed brain pathologies in dementia: the BrainNet Europe consortium experience. Dement Geriatr Cogn Disord 26 (2008) 343-350
15. Jellinger K.A., and Attems J. Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. Acta Neuropathol 115 (2008) 427-436
16. Ishizawa T., Mattila P., Davies P., Wang D., and Dickson D.W. Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol 62 (2003) 389-397
17. Nakashima-Yasuda H., Uryu K., Robinson J., et al. Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol 114 (2007) 221-229
18. Yamamura Y., Hattori N., Matsumine H., Kuzuhara S., and Mizuno Y. Autosomal recessive early-onset parkinsonism with diurnal fluctuation: clinicopathologic characteristics and molecular genetic identification. Brain Dev 22 suppl 1 (2000) S87-S91
19. Mori H., Kondo T., Yokochi M., et al. Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q. Neurology 51 (1998) 890-892
20. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., and Goedert M. Alpha-synuclein in Lewy bodies. Nature 388 (1997) 839-840
21. Braak H., Sandmann-Keil D., Gai W., and Braak E. Extensive axonal Lewy neurites in Parkinson's disease: a novel pathological feature revealed by alpha-synuclein immunocytochemistry. Neurosci Lett 265 (1999) 67-69
22. Irizarry M.C., Growdon W., Gomez-Isla T., et al. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity. J Neuropathol Exp Neurol 57 (1998) 334-337
23. Saito Y., Kawashima A., Ruberu N.N., et al. Accumulation of phosphorylated alpha-synuclein in aging human brain. J Neuropathol Exp Neurol 62 (2003) 644-654
24. Arawaka S., Saito Y., Murayama S., and Mori H. Lewy body in neurodegeneration with brain iron accumulation type 1 is immunoreactive for alpha-synuclein. Neurology 51 (1998) 887-889
25. Galvin J.E., Giasson B., Hurtig H.I., Lee V.M., and Trojanowski J.Q. Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology. Am J Pathol 157 (2000) 361-368
26. Alafuzoff I., Parkkinen L., Al-Sarraj S., et al. Assessment of alpha-synuclein pathology: a study of the BrainNet Europe Consortium. J Neuropathol Exp Neurol 67 (2008) 125-143
27. Beach T.G., White C.L., Hamilton R.L., et al. Evaluation of alpha-synuclein immunohistochemical methods used by invited experts. Acta Neuropathol 116 (2008) 277-288
28. Croisier E., Elfant Mres D., Deprez M., et al. Comparative study of commercially available anti-alpha-synuclein antibodies. Neuropathol Appl Neurobiol 32 (2006) 351-356
29. Tu P.H., Galvin J.E., Baba M., et al. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann Neurol 44 (1998) 415-422
30. Gai W.P., Power J.H., Blumbergs P.C., and Blessing W.W. Multiple-system atrophy: a new alpha-synuclein disease?. Lancet 352 (1998) 547-548
31. Spillantini M.G. Parkinson's disease, dementia with Lewy bodies and multiple system atrophy are alpha-synucleinopathies. Parkinsonism Relat Disord 5 (1999) 157-162
32. Fumimura Y., Ikemura M., Saito Y., et al. Analysis of the adrenal gland is useful for evaluating pathology of the peripheral autonomic nervous system in Lewy body disease. J Neuropathol Exp Neurol 66 (2007) 354-362
33. Ikemura M., Saito Y., Sengoku R., et al. Lewy body pathology involves cutaneous nerves. J Neuropathol Exp Neurol 67 (2008) 945-953
34. Orimo S., Uchihara T., Nakamura A., et al. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. Brain 131 (2008) 642-650
35. Braak H., Del Tredici K., Rub U., de Vos R.A., Steur E.J., and Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24 (2003) 197-211
36. Braak H., de Vos R.A., Bohl J., and Del Tredici K. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett 396 (2006) 67-72
37. Braak H., and Del Tredici K. Neuroanatomy and pathology of sporadic Parkinson's disease. Adv Anat Embryol Cell Biol 201 (2009) 1-119
38. Bloch A., Probst A., Bissig H., Adams H., and Tolnay M. Alpha-synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects. Neuropathol Appl Neurobiol 32 (2006) 284-295
39. Kosaka K., Tsuchiya K., and Yoshimura M. Lewy body disease with and without dementia: a clinicopathological study of 35 cases. Clin Neuropathol 7 (1988) 299-305
40. McKeith I.G., Galasko D., Kosaka K., et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47 (1996) 1113-1124
41. Beach T.G., Adler C.H., Lue L., et al. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol 117 (2009) 613-634
42. Ballard C., Ziabreva I., Perry R., et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology 67 (2006) 1931-1934
43. Zaccai J., Brayne C., McKeith I., Matthews F., and Ince P.G. Patterns and stages of alpha-synucleinopathy: relevance in a population-based cohort. Neurology 70 (2008) 1042-1048
44. Halliday G., Hely M., Reid W., and Morris J. The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol 115 (2008) 409-415
45. Parkkinen L., Pirttila T., and Alafuzoff I. Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathol 115 (2008) 399-407
46. Gelb D.J., Oliver E., and Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 56 (1999) 33-39
47. Daniel S.E., and Lees A.J. Parkinson's Disease Society Brain Bank, London: overview and research. J Neural Transm Suppl 39 (1993) 165-172
48. Rudow G., O'Brien R., Savonenko A.V., et al. Morphometry of the human substantia nigra in ageing and Parkinson's disease. Acta Neuropathol 115 (2008) 461-470
49. Greffard S., Verny M., Bonnet A.M., Seilhean D., Hauw J.J., and Duyckaerts C. A stable proportion of Lewy body bearing neurons in the substantia nigra suggests a model in which the Lewy body causes neuronal death. Neurobiol Aging (2008) 10.1016/j.neurobiolaging.2008.03.015 published online May 3.
50. Leverenz J.B., Hamilton R., Tsuang D.W., et al. Empiric refinement of the pathologic assessment of Lewy-related pathology in the dementia patient. Brain Pathol 18 (2008) 220-224
51. Alafuzoff I., Ince P.G., Arzberger T., et al. Staging/typing of Lewy body related alpha-synuclein pathology: a study of the BrainNet Europe Consortium. Acta Neuropathol 117 (2009) 635-652
52. Jellinger K.A. The morphological basis of mental dysfunction in Parkinson's disease. J Neurol Sci 248 (2006) 167-172
53. Jellinger K.A., and Attems J. Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies?. Acta Neuropathol 112 (2006) 253-260
54. Aarsland D., Ballard C.G., and Halliday G. Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity?. J Geriatr Psychiatry Neurol 17 (2004) 137-145
55. Guo L., Itaya M., Takanashi M., Mizuno Y., and Mori H. Relationship between Parkinson disease with dementia and dementia with Lewy bodies. Parkinsonism Relat Disord 11 (2005) 305-309
56. Tsuboi Y., and Dickson D.W. Dementia with Lewy bodies and Parkinson's disease with dementia: are they different?. Parkinsonism Relat Disord 11 suppl 1 (2005) S47-S51
57. Iwanaga K., Wakabayashi K., Yoshimoto M., et al. Lewy body-type degeneration in cardiac plexus in Parkinson's and incidental Lewy body diseases. Neurology 52 (1999) 1269-1271
58. Ross G.W., Petrovitch H., Abbott R.D., et al. Parkinsonian signs and substantia nigra neuron density in decendents elders without PD. Ann Neurol 56 (2004) 532-539
59. Markesbery W.R., Jicha G.A., Liu H., and Schmitt F.A. Lewy body pathology in normal elderly subjects. J Neuropathol Exp Neurol 68 (2009) 816-822
60. Uchiyama M., Isse K., Tanaka K., et al. Incidental Lewy body disease in a patient with REM sleep behavior disorder. Neurology 45 (1995) 709-712
61. Fujishiro H., Frigerio R., Burnett M., et al. Cardiac sympathetic denervation correlates with clinical and pathologic stages of Parkinson's disease. Mov Disord 23 (2008) 1085-1092
62. Del Tredici K., Rub U., De Vos R.A., Bohl J.R., and Braak H. Where does parkinson disease pathology begin in the brain?. J Neuropathol Exp Neurol 61 (2002) 413-426
63. Leverenz J.B., Fishel M.A., Peskind E.R., et al. Lewy body pathology in familial Alzheimer disease: evidence for disease- and mutation-specific pathologic phenotype. Arch Neurol 63 (2006) 370-376
64. Uchikado H., Lin W.L., DeLucia M.W., and Dickson D.W. Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy. J Neuropathol Exp Neurol 65 (2006) 685-697
65. Dickson D.W., Bergeron C., Chin S.S., et al. Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol 61 (2002) 935-946
66. Litvan I., Hauw J.J., Bartko J.J., et al. Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol 55 (1996) 97-105
67. Gibb W.R., and Lees A.J. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 51 (1988) 745-752
68. Beach T.G., Adler C.H., Sue L.I., et al. Reduced striatal tyrosine hydroxylase in incidental Lewy body disease. Acta Neuropathol 115 (2008) 445-451
69. DelleDonne A., Klos K.J., Fujishiro H., et al. Incidental Lewy body disease and preclinical Parkinson disease. Arch Neurol 65 (2008) 1074-1080
70. Parkkinen L., Kauppinen T., Pirttila T., Autere J.M., and Alafuzoff I. Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol 57 (2005) 82-91
71. Parkkinen L., Pirttila T., Tervahauta M., and Alafuzoff I. Widespread and abundant alpha-synuclein pathology in a neurologically unimpaired subject. Neuropathology 25 (2005) 304-314
72. Tsuboi Y., Uchikado H., and Dickson D.W. Neuropathology of Parkinson's disease dementia and dementia with Lewy bodies with reference to striatal pathology. Parkinsonism Relat Disord 13 suppl 3 (2007) S221-S224
73. Halliday G.M., Ophof A., Broe M., et al. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. Brain 128 (2005) 2654-2664
74. Mosharov E.V., Larsen K.E., Kanter E., et al. Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron 62 (2009) 163-164
75. Matzuk M.M., and Saper C.B. Preservation of hypothalamic dopaminergic neurons in Parkinson's disease. Ann Neurol 18 (1985) 552-555
76. Cookson M.R. Alpha-synuclein and neuronal cell death. Mol Neurodegener 4 (2009) 9
77. Lee H.J., Khoshaghideh F., Patel S., and Lee S.J. Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway. J Neurosci 24 (2004) 1888-1896
78. Chu Y., Dodiya H., Aebischer P., Olanow C.W., and Kordower J.H. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol Dis 35 (2009) 385-398
79. McGeer P.L., and McGeer E.G. The alpha-synuclein burden hypothesis of Parkinson disease and its relationship to Alzheimer disease. Exp Neurol 212 (2008) 235-238
80. Saha A.R., Hill J., Utton M.A., et al. Parkinson's disease alpha-synuclein mutations exhibit defective axonal transport in cultured neurons. J Cell Sci 117 (2004) 1017-1024
81. Chung C.Y., Koprich J.B., Siddiqi H., and Isacson O. Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. J Neurosci 29 (2009) 3365-3373
82. Duda J.E., Giasson B.I., Mabon M.E., Lee V.M., and Trojanowski J.Q. Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann Neurol 52 (2002) 205-210
83. Roy S., Zhang B., Lee V.M., and Trojanowski J.Q. Axonal transport defects: a common theme in neurodegenerative diseases. Acta Neuropathol 109 (2005) 5-13
84. Utton M.A., Noble W.J., Hill J.E., Anderton B.H., and Hanger D.P. Molecular motors implicated in the axonal transport of tau and alpha-synuclein. J Cell Sci 118 (2005) 4645-4654
85. Giasson B.I., Forman M.S., Higuchi M., et al. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300 (2003) 636-640
86. Cookson M.R., and van der Brug M. Cell systems and the toxic mechanism(s) of alpha-synuclein. Exp Neurol 209 (2008) 5-11
87. Uversky V.N. Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation. J Neurochem 103 (2007) 17-37
88. Kordower J.H., Chu Y., Hauser R.A., Freeman T.B., and Olanow C.W. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 14 (2008) 504-506
89. Li J.Y., Englund E., Holton J.L., et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 14 (2008) 501-503
90. Aguzzi A. Cell biology: beyond the prion principle. Nature 459 (2009) 924-925
91. McGeer P.L., and McGeer E.G. Glial reactions in Parkinson's disease. Mov Disord 23 (2008) 474-483
92. McGeer P.L., Itagaki S., Boyes B.E., and McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38 (1988) 1285-1291
93. Orr C.F., Rowe D.B., and Halliday G.M. An inflammatory review of Parkinson's disease. Prog Neurobiol 68 (2002) 325-340